At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 111 enrolled

Drug / intervention

NUC-3373 + leucovorin +8 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03428958

NCT03428958Phase 2Completed

Compare CT.gov

A Phase Ib/II Open Label Study to Assess the Safety and Pharmacokinetics of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Agents Used in Colorectal Cancer Treatment

NuCana plc·interventional·Posted Feb 12, 2018·Updated Apr 23, 2025

In Brief

A Phase 2 clinical trial evaluating NUC-3373 + leucovorin, NUC-3373, and 7 other interventions for Colorectal Cancer and 4 related conditions. Completed, enrolled 111 participants across 10 sites in 3 countries.

Detailed Summary

This is a three-part study of NUC-3373 administered by intravenous (IV) infusion across two administration schedules, either as monotherapy or as part of various combinations with agents commonly used to treat CRC (leucovorin, oxaliplatin, irinotecan, bevacizumab, cetuximab and panitumumab). The primary objective is to identify a recommended dose and schedule for NUC-3373 when combined with these agents.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsColorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal

CountriesFrance, United Kingdom, United States

Collaborators--

Timeline

Phase 2CompletedFinished

201820192020202120222023202420252026

First PostedFeb 2018

Enrollment StartOct 2018

Primary CompletionMar 2024

Study CompletionMar 2024

TodayJul 2026

First PostedFeb 12, 2018

Enrollment StartOct 5, 2018

Primary CompletionMar 19, 2024

Study CompletionMar 21, 2024

TodayJul 2, 2026

Enrollment to primary: 5.5 yearsPosted 8.4 years ago

Interventions

NUC-3373 + leucovorindrug

NUC-3373 + leucovorin

NUC-3373drug

NUC-3373

NUFOXdrug

NUC-3373 + oxaliplatin

NUFOX + VEGF pathway inhibitordrug

NUC-3373 + oxaliplatin + bevacizumab

NUFOX + EGFR inhibitordrug

NUC-3373 + oxaliplatin + cetuximab/panitumumab

NUFIRIdrug

NUC-3373 + irinotecan

NUFIRI + VEGF pathway inhibitordrug

NUC-3373 + irinotecan + bevacizumab

NUFIRI + EGFR inhibitordrug

NUC-3373 + irinotecan + cetuximab/panitumumab

NUC-3373 + bevacizumabdrug

NUC-3373 + bevacizumab